Pregabalin Capsule
Product Images NDC 60760-485

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-485). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Preg (Pregabalin 60760 485 60)

This is a description of Pregabalin capsules manufactured by ScoGen Pharmaceuticals in Hauppauge, NY. Each capsule contains either 75mg or 225mg of Pregabalin. The capsules are packaged in bottles containing 60 or 50 capsules. The lot number of each bottle is provided. This product should be stored at room temperature. The document also includes a reference to a "managed pharmacy program."*

FDA Label Image

Figure 1 (Pregabalin Fig01)

FDA Label Image

Figure 2 (Pregabalin Fig02)

The text provides a table or chart listing percentage improvement in pain from the baseline of patients taking Pregabalin 160 mg for 3 days. The table has a range of numbers from 2 to 100. There are also some numerical values of 220, 23, 20, and 280 with no clear indication of what they represent. The text also mentions the word "Facebo" which could be a misspelling of the social media platform "Facebook", but it is unclear how it relates to the rest of the information. Overall, this text provides limited and unclear information, making it not very useful.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

This document appears to be a chart showing different medications and dosages, along with a percentage of patients who experienced improvement in pain. The medications listed include Pregatalin and Pregabalin, administered in varying dosages, as well as Flaosbo (which may be a misspelling or error). The chart contains some numerical values and dates but without proper context, it is not clear what these values represent.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

FDA Label Image

Figure 5 (Pregabalin Fig05)

This is a study report that compares the effectiveness of Fregabalin, Pregataiin and placebo in reducing pain. The doses administered were Fregabalin 100 mg thrice daily, Pregataiin 80 mg thrice daily, and placebo respectively. The chart shows that 83.8% of patients improved when treated with Fregabalin, whereas the percentage of improvement was not available for Pregataiin and placebo. Additionally, the table displays the percentage of pain improvement from baseline, where the highest percentage of improvement was achieved with Fregabalin.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

The text represents a table with headers "L Study", "E1 Study", "E3 Study", and "S5". The rest of the table contains dosage information for Placebo, SOmg/day, 150mg/day, 300mg/day, and 600mg/day. The text also mentions that the results were statistically significant compared to the placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

FDA Label Image

Figure 9 (Pregabalin Fig08)

The text shows a graph comparing the percentage of patients who improved their pain levels from a baseline using Pregabalin at a daily dose of 300mg or 450mg, as well as a placebo. There is an axis indicating the percent improvement in pain from a baseline, ranging from 20 to 80 percent. No further information is available from the text.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

This is a chart that displays the estimated percentage of subjects without LTR over a period of 120 days. Two treatments are being compared: "Progabain" and "Placebo". The x-axis shows the days of the study, while the y-axis shows the percentage of subjects without LTR.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

FDA Label Image

Figure 12 (Pregabalin Fig11)

The text represents a chart or a graph showing the percent of subjects improved from baseline to week 16 BOCF for Pregabalin and Placebo. The values range from 100% to 280%.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

This text appears to be part of a medical calculation for estimating a patient's creatinine clearance (CLCT), which is a measure of kidney function. The formula involves subtracting the patient's age in years from 140, then multiplying that result by the patient's weight in kilograms. For female patients, the result is then multiplied by 0.85. The next step is to multiply the result by the serum creatinine level (in milligrams per deciliter) and finally by 72. This calculation is often used to determine appropriate drug dosages for patients with impaired renal function.*

FDA Label Image

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.